Jobaaj Stories
Mirati Therapeutics is a biotechnology company that develops and delivers therapeutics which target the genetic and immunological causes of cancer.
The company is headquartered in San Diego, California, US and operates in Canada and Netherlands as well. It partners with major names like Zai Labs, Beigene, Sanofi, Novartis, Bristol Myers Squibb among several others.
Its main programs revolve around inhibitors like KRAS, Sitravatinib and MRTX1719 which are used for the treatment of cancer. The company is also involved in clinical trials to study the effectiveness of its therapeutics and programs while also focusing on improving them.
It has also developed a medicine called Krazati. The medication is used to treat patients with locally advanced or metastatic non-small lung cancer.
For the full year of 2022, the company had revenues of $0.7 million from products while licensing and collaboration revenues reached $11.7 million. However, the same is significantly lower than the $72.1 million reported last year.
Moreover, with R&D and general expenses reaching a total of $771.4 million, the company suffered a loss of $740.9 million for CY22, up 27.3% YoY. This meant a per share loss of $13.18 per shareholder.
The stock of Mirati Therapeutics closed at $37.34 per share, down 3.44% yesterday.
- Aman Agarwal
